Castle Biosciences Appoints New Chief Medical Officer
Ticker: CSTL · Form: 8-K · Filed: 2024-03-27T00:00:00.000Z
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Castle Biosciences CMO out, new CMO in. Big changes coming?
AI Summary
Castle Biosciences, Inc. announced on March 26, 2024, the departure of its Chief Medical Officer, Dr. Derek J. Maathuis. The company also announced the appointment of Dr. Michael J. Murphy as the new Chief Medical Officer, effective immediately. Dr. Murphy brings extensive experience in medical affairs and product development to Castle Biosciences.
Why It Matters
A change in key executive leadership, especially the Chief Medical Officer, can signal shifts in the company's strategic direction regarding research, development, and clinical trials.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Castle Biosciences, Inc. (company) — Registrant
- Dr. Derek J. Maathuis (person) — Departing Chief Medical Officer
- Dr. Michael J. Murphy (person) — Appointed Chief Medical Officer
- March 26, 2024 (date) — Date of earliest event reported
FAQ
Who is the new Chief Medical Officer for Castle Biosciences?
Dr. Michael J. Murphy has been appointed as the new Chief Medical Officer for Castle Biosciences, effective immediately.
When was the change in Chief Medical Officer reported?
The change was reported on March 26, 2024, as the date of the earliest event.
Who previously held the position of Chief Medical Officer?
Dr. Derek J. Maathuis previously held the position of Chief Medical Officer.
What is Castle Biosciences' principal executive office address?
Castle Biosciences' principal executive office is located at 505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546.
What is the SIC code for Castle Biosciences?
The Standard Industrial Classification (SIC) code for Castle Biosciences is 8071, which falls under SERVICES-MEDICAL LABORATORIES.
Filing Stats: 1,865 words · 7 min read · ~6 pages · Grade level 12.4 · Accepted 2024-03-27 17:05:02
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share CSTL The Nasdaq
- $10.0 million — t provides for (i) on the Closing Date, $10.0 million aggregate principal amount of term loan
- $25.0 million — ate until March 31, 2025, an additional $25.0 million term loan facility available at the Com
- $350,000 — eive an initial grant having a value of $350,000, which shall be comprised of a restrict
- $45,000 — e to receive an annual cash retainer of $45,000 for his service on the Board and an ann
Filing Documents
- d782226d8k.htm (8-K) — 35KB
- d782226dex101.htm (EX-10.1) — 315KB
- 0001193125-24-078933.txt ( ) — 559KB
- cstl-20240326.xsd (EX-101.SCH) — 3KB
- cstl-20240326_lab.xml (EX-101.LAB) — 18KB
- cstl-20240326_pre.xml (EX-101.PRE) — 11KB
- d782226d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CASTLE BIOSCIENCES, INC. By: /s/ Frank Stokes Frank Stokes Chief Financial Officer Date: March 27, 2024